Pharmaron Beijing (300759) Q1 2025 earnings summary

Executive summary

• Achieved revenue of ¥3.10 billion in Q1 2025, up 16.03% year-over-year, with net profit attributable to shareholders rising 32.54% to ¥305.58 million.

• Laboratory and CMC (small molecule CDMO) services saw double-digit growth in new contract signings, both exceeding 10% year-over-year.

• Revenue from global top 20 pharmaceutical clients grew 29.05% year-over-year, accounting for 14.71% of total revenue.

Financial highlights

• Operating cash flow increased 14.38% year-over-year to ¥852.83 million.

• Adjusted net profit (non-IFRS) attributable to shareholders was ¥349.44 million, up 3.14% year-over-year.

• Basic EPS rose 33.54% to ¥0.1736; diluted EPS up 33.51% to ¥0.1733.

• Gross margin for laboratory services was 45.54%, up from 44.14% a year ago.

Outlook and guidance

• New contract signings for laboratory and CMC services both grew over 10% year-over-year, indicating strong demand and positive business momentum.